Autonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan

MT Newswires Live

Jun 05

Autonomix Medical (AMIX) said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.

Autonomix said it is on track to commence enrollment this month.

The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.

Autonomix Medical shares were 14% lower in recent trading.

Price: 1.38, Change: -0.24, Percent Change: -14.81

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2541193079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541193079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541193079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541193079","market":"sh","top_or_hot":-1,"title":"Autonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan","media":"MT Newswires Live","content":"<html><body><p> Autonomix Medical (AMIX) said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.</p><p>Autonomix said it is on track to commence enrollment this month.</p><p>The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.</p><p>Autonomix Medical shares were 14% lower in recent trading.</p><p>Price: 1.38, Change: -0.24, Percent Change: -14.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Autonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAutonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-05 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Autonomix Medical (AMIX) said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.</p><p>Autonomix said it is on track to commence enrollment this month.</p><p>The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.</p><p>Autonomix Medical shares were 14% lower in recent trading.</p><p>Price: 1.38, Change: -0.24, Percent Change: -14.81</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2541193079","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541193079","pubTimestamp":1749134188,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Autonomix Medical  said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.Autonomix said it is on track to commence enrollment this month.The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.Autonomix Medical shares were 14% lower in recent trading.Price: 1.38, Change: -0.24, Percent Change: -14.81","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","AMIX":"Autonomix Medical Inc"},"translate_title":"Autonomix Medical获准在乌兹别克斯坦开始测试癌症相关疼痛的治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMIX":0.9},"content_text":"Autonomix Medical (AMIX) said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.Autonomix said it is on track to commence enrollment this month.The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.Autonomix Medical shares were 14% lower in recent trading.Price: 1.38, Change: -0.24, Percent Change: -14.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}